依托咪酯对肺癌患者外周静脉血血小板活化标志物水平的影响

目的 探讨依托咪酯对肺癌患者外周静脉血血小板活化标志物CD62p和CD41/61的影响.方法 40例肺癌患者随机分为4组(A组、B组、C组、D组)抽取外周静脉血,B组、C组和D组的血标本分别加入0.2、2、20 mg/L依托咪酯,抽取10名健康志愿者外周静脉血作为对照组(E组,n=10),E组和A组不加人药物.应用流式细胞仪测定血小板活化标志物CD62p和CD41/61的表达量.结果 5组患者的年龄、性别、体重,血小板计数和凝血时间差异均无统计学意义.与E组血小板活化标志物CD62p(3.3 ±1.9)%、CD41/61(93.1+3.4)%比较,A组血小板活化标志物CD62p(37.1±20.3)%、CD41/61(97.2±1.4)%表达增高(P<0.01);与A组血小板活化标志物比较,C组CD62p(20.9+9.2)%表达降低(RO.05),D组CD62p(17.9±15.6)%表达明显降低(P<0.01),C组、D组CD41/61无明显改变,B组血小板活化标志物无明显变化(P>0.05).结论 肺癌患者外周静脉血血小板活化标志物CD62p、CD41/61表达高于正常人,在体外依托咪酯2 mg,L和20 mg/L可以抑制CD62p表达,抑制血小板的活化.

Effect of etomidate on expression of activation makers of platelet in peripheral venom blood in patients with lung cancer

Objective To investigate the effect of etomidate on the expression of activation makers of platelet CD62p and CD41/ 61 in peripheral venous blood in patients with lung cancer. Methods Peripheral venous blood samples were taken from 10 healthy volunteers (group E) and 40 patients with lung cancer. The 40 patients with lung cancer were randomly divided into 4 groups (n=10 each): groups A, B, C and D. The blood samples in groups E and A were incubated without etomidate, while the blood samples in groups B, C and D were incubated with etomidate 0.2, 2 and 20 mg/L, respectively. The inhibitory effects of etomidate on expression of activation makers of platelet CD62p and CD41/61 were determined by flow cytometry. Results The five groups were comparable with respect to age, body weight, platelet count and coagulation time. The expression of C D62p (37.1±20.3) %、 CD41/61 (97.2±1.4) % on the platelet surface was significantly increased in patients with lung cancer than the expression of CD62p (3.3±1.9)%, CD41/61 (93.1±3.4)% in healthy adults (P<0.01).Compare with group A, the expression of activation makers of platelet CD62p (20.9±9.2)%on the platelet surface in group C was decreased (P<0.05)and the expression of activation makers of platelet CD62p (17.9±15.6)% in group D was significantly decreased(P<0.01),whereas etomidate 0.2 mg/L had no significantly effect on CD62p and CD41/61. Conclusion The expression of activation makers of plateleta significantly increased in patients with lung cancer compared with healthy adults. In vitro,etomidate 2 and 20 mg/L can inhibit the expression of CD62p.